Mr. YANG Tao mainly focuses on Hong Kong and US capital markets, corporate law and listed company compliance matters. He specializes in Hong Kong IPOs, dual primary/secondary listings in the US and Hong Kong, US IPOs, GDR and other follow-on offerings. He leads prospectus drafting including core sections of business, MD&A, risk factors, industry and other sections of the prospectuses. He drafts and negotiates underwriting documents on behalf of both issuers and underwriters. He engages in communication with regulatory authorities in the US, Hong Kong and mainland China. He also advises clients on HK and US post-listing compliance matters including annual reports, interim reports, quarterly reports and US filings such as 20-F/6-K and 13D/13G/13F filings. Mr. YANG Tao specializes in prospectus drafting for companies in the hard tech, new economy and bio-pharma industries. His representative deals include the HKEX listing of 18C hard tech companies Black Sesame, Huayan Robotics, Deepexi and CiDi, 18A bio and medical devices companies Edge Medical, Recbio and MicroTech, Hong Kong dual-listing companies JD.com, Bilibili, KANZHUN and OneConnect, and other top-tier hard tech, TMT, A+H and consumer product companies including SenseTime, RoboSense, InnoScience, UniSound, Kuaishou, SANY, Wuxi Lead, SICC, Haier Smart Home and Nongfu Spring.

• Represented SenseTime Group (WVR structure) on its Hong Kong public offering and international placing, and red chip stock listing on the HKEX (Drafted prospectus)
• Represented Black Sesame on its Hong Kong public offering and international placing under Chapter 18C, and red chip stock listing on the HKEX (Drafted prospectus)
• Represented Huayan Robotics (formerly Han’s Robot) on its Hong Kong public offering and international placing under Chapter 18C, and H-share listing on the HKEX (Drafted prospectus)
• Represented CiDi on its Hong Kong public offering and international placing under Chapter 18C, and H-share listing on the HKEX (Drafted prospectus)
• Represented Deepexi on its Hong Kong public offering and international placing under Chapter 18C, and H-share listing on the HKEX (Drafted prospectus)
• Represented RoboSense on its Hong Kong public offering and international placing, and red chip stock listing on the HKEX (Drafted prospectus)
• Represented InnoScience on its Hong Kong public offering and international placing, and H-share listing on the HKEX (Drafted prospectus)
• Represented UniSound on its Hong Kong public offering and international placing, and H-share listing on the HKEX (Drafted prospectus)
• Represented SciClone Pharmaceuticals on its Hong Kong public offering and international placing, and red chip stock listing on the HKEX (Drafted prospectus)
• Represented SANY on its Hong Kong public offering and international placing, and H-share listing on the HKEX (Drafted prospectus)
• Represented Wuxi Lead on its Hong Kong public offering and international placing, and H-share listing on the HKEX (Drafted prospectus)
• Represented SICC on its Hong Kong public offering and international placing, and H-share listing on the HKEX (Drafted prospectus)
• Represented Haier Smart Home on its H-share listing by introduction on the HKEX (Drafted prospectus)
• Represented Shenwan Hongyuan Group on its Hong Kong public offering and international placing, and H-share listing on the HKEX (Drafted prospectus)
• Represented Huatai Securities on its GDR offering and listing on the London Stock Exchange (Drafted prospectus)
• Represented the sponsors on Kuaishou’s (WVR structure) Hong Kong public offering and international placing, and red chip stock listing on the HKEX
• Represented the sponsors on Nongfu Spring’s Hong Kong public offering and international placing, and H-share listing on the HKEX
• Represented the sponsors on JD.com’s (WVR structure) Hong Kong public offering and international placing, and secondary listing on the HKEX
• Represented the sponsors on Bilibili’s (WVR structure) Hong Kong public offering and international placing, and secondary listing on the HKEX
• Represented the sponsors on KANZHUN’s (WVR structure) dual primary listing by introduction on the HKEX
• Represented the sponsors on OneConnect’s dual primary listing by introduction on the HKEX
• Represented the sponsors on Edge Medical’s Hong Kong public offering and international placing under Chapter 18A, and H-share listing on the HKEX
• Represented the sponsors on Recbio’s Hong Kong public offering and international placing under Chapter 18A, and H-share listing on the HKEX
• Represented the sponsors on MicroTech’s Hong Kong public offering and international placing under Chapter 18A, and H-share listing on the HKEX
• Represented the sponsors on Adicon’s Hong Kong public offering and international placing, and red chip stock listing on the HKEX
• Represented the sponsors on PATEO’s Hong Kong public offering and international placing, and H-share listing on the HKEX
• Represented the sponsors on Dongguan Rural Commercial Bank’s Hong Kong public offering and international placing, and H-share listing on the HKEX
• Represented the underwriters on Genetron’s SEC-registered IPO and Nasdaq listing